Nuvation Bio Inc. filings document the regulatory record of a public oncology company with Class A common stock listed on the New York Stock Exchange. The company's 8-K disclosures cover operating and financial results, material agreements, clinical and regulatory updates for taletrectinib and safusidenib, pipeline decisions involving its drug-drug conjugate program, and other material-event disclosures.
Proxy materials describe board elections, auditor ratification, executive compensation votes, shareholder voting procedures, and governance matters. Capital-structure filings identify the company's registered securities, including Class A common stock and historical warrant-related disclosures, while Form 25 records document removal of a warrant class from exchange listing and registration.
Nuvation Bio Inc. reported that director Kim D. Blickenstaff received a grant of stock options. The award covers 123,397 options to buy Class A common stock at an exercise price of $4.79 per share, expiring on May 20, 2036.
All of the options vest 100% on the earlier of May 21, 2026 or the next shareholder annual meeting, as long as the director remains in continuous service. Following this grant, the filing shows 123,397 derivative securities held directly, with no open‑market purchases or sales reported.
Nuvation Bio Inc. director Robert B. Bazemore received a stock option grant covering 123,397 shares of Class A common stock. The option has an exercise price of $4.79 per share and expires on May 20, 2036. All shares vest 100% on the earlier of May 21, 2026, or the next shareholder annual meeting, subject to his continuous service. This is a compensation-related award, with no open-market share purchases or sales reported.
Nuvation Bio Inc. director Xiangmin Cui reported receiving a stock option grant on Class A common stock. The award covers 123,397 options with an exercise price of $4.79 per share and expires on May 20, 2036. Following this grant, Cui holds 123,397 derivative securities linked to the company’s Class A common stock.
According to the terms, 100% of the options will vest on the earlier of May 21, 2026 or the next shareholder annual meeting, provided Cui remains in continuous service through that vesting date. This filing reflects a compensation-related acquisition rather than an open-market purchase or sale.
Nuvation Bio Inc. director Xiangmin Cui corrected a prior insider report to show a grant of 76,923 stock options for Class A common stock received on February 27, 2026. These options have a $5.91 exercise price, expire on February 26, 2036, and vest in 24 monthly installments starting from January 1, 2026.
Nuvation Bio reported a strong first quarter of 2026, moving to net income of $5.4 million after a net loss of $53.2 million a year earlier. Total revenue rose to $83.2 million, driven by initial U.S. sales of IBTROZI and a large increase in collaboration and license revenue.
Net product revenue from U.S. sales of IBTROZI (taletrectinib) reached $18.5 million, while collaboration and license agreements revenue climbed to $64.7 million, largely due to an upfront payment under the Eisai agreement. The company ended March 31, 2026 with $533.7 million in cash, cash equivalents, and marketable securities.
Nuvation Bio highlighted updated clinical data showing durable responses for IBTROZI in ROS1‑positive NSCLC and announced acquisition of Japan rights to safusidenib, supporting its global development. Research and development spending increased to $35.0 million, and selling, general and administrative expenses were $38.3 million as the company invests behind its oncology portfolio.
Nuvation Bio Inc. reported a sharp turnaround for the quarter ended March 31, 2026, posting net income of $5.4M compared with a loss of $53.2M a year earlier. Total revenue rose to $83.2M from $3.1M, driven by U.S. IBTROZI product sales and a major taletrectinib license deal with Eisai.
Product revenue reached $18.5M, while collaboration and license revenue increased to $64.7M, including about $58.7M of upfront license revenue from Eisai. Operating cash flow improved to a positive $5.1M. The company ended the quarter with $533.7M in cash, cash equivalents and marketable securities and continues to invest heavily in research and development and commercializing IBTROZI.
Nuvation Bio Inc. chief regulatory officer Kerry Wentworth exercised options and sold shares in a planned transaction. On April 17, 2026, Wentworth exercised options to acquire 36,750 shares of Class A common stock at $2.93 per share, then sold 36,750 shares in open-market trades at a weighted-average price of $5.0144 under a Rule 10b5-1 trading plan. After these transactions, Wentworth directly owns 53,000 shares of Nuvation Bio Class A common stock.
Nuvation Bio Inc. chief medical officer Dongfang Liu reported an exercise-and-sell transaction in Class A common stock. Liu exercised stock options to acquire 50,000 shares at $1.94 per share, then sold 50,000 shares in open-market trades at a weighted-average price of $5.02 per share.
The sales, executed at prices ranging from $5.00 to $5.07, were made under a pre-arranged Rule 10b5-1 trading plan dated December 4, 2025. After these transactions, Liu holds 18,000 shares of Class A common stock and 430,000 stock options expiring on February 27, 2033.
Morgan Stanley Smith Barney LLC filed a Form 144 reporting a proposed sale of 36,750 shares of Common Stock via the exercise of stock options on 04/17/2026.
The filing also records that 200,000 shares were sold under a 10b5-1 plan on 04/06/2026 by Kerry Wentworth for $903,550.